1. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001, 345: 1318-1330.

2. Durack DT. Prevention of Infective Endocarditis. N Engl J Med 1995, 332: 38-44.

3. Hall G, Heimdahl A, Nord CE. Bacteremia after oral surgery and antibiotic prophylaxis for endocarditis. Clin Infect Dis 1999, 29: 1-8.

4. Lewis T, Grant RT. Observations relating to subacute infective endocarditis. Heart 1923, 10: 21-99.

5. Okell CC, Elliott SD. Bacteraemia and oral sepsis wit special reference to the aetiology of subacute endocarditis. Lancet 1935, 2: 869-872.

6. Burket LW, Burn CG. Bacteremias following dental extraction. Demonstration of source of bacteria by means of a non-pathogen (Serratia marcescens). J Dent Res 1937, 16: 521-530.

7. Wahlmann U, Al-Nawas B, Jutte M, et al. Clinical and microbiological efficacy of single dose cefuroxime prophylaxis for dental surgical procedures. Int J Antimicrob Agents 1999, 12: 253-256.

8. Durack DT. Antibiotics for prevention of endocarditis during dentistry: time to scale back? Ann Intern Med 1998, 129: 829-831.

9. Blanco-Carrion A. Bacterial endocarditis prophylaxis. Med Oral Patol Oral Cir Bucal 2004, 9: 44-51.

10. Press N, Montessori V. Prophylaxis for infective endocarditis. Who needs it? How effective is it? Can Fam Physicians 2000, 46: 2248-2255.

11. Perlman BB, Freedman LR. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J Biol Med 1971, 44: 206-213.

12. Heraief E, Glauser MP, Freedman LR. Natural history of aortic valve endocarditis in rats. Infect Imun 1982, 37: 127-131.

13. Moreillon P. Endocarditis prophylaxis revisited: experimental evidence of efficacy and new Swiss recommendations. Swiss Working Group for Endocarditis Prophylaxis. Schweiz Med Wochenschr 2000, 130: 1013-1026.

14. Moreillon P, Overholser CD, Malinverni R, et al. Predictors of endocarditis in isolates from cultures of blood following dental extractions in rats with peri-odontal disease. J Infect Dis 1988, 157: 990-995.

15. Baddour LM. Virulence factors among gram-positive bacteria in experimental endocarditis. Infect Imun 1994, 62: 2143-2148.

16. Berney P, Francioli P. Successful prophylaxis of experimental streptococcal endocarditis with single-dose amoxicillin administered after bacterial challenge. J Infect Dis 1990, 161: 281-285.

17. Durack DT, Beeson PB. Experimental bacterial endocarditis. I. Colonization of a sterile vegetation. Br J Exp Pathol 1972, 53: 44-49.

18. Pujadas R, Escriva E, Jane J, et al. Comparative capacity of orally administered amoxicillin and parenterally administered penicillin-streptomycin to protect rabbits against experimentally induced streptococcal endocarditis. Antimicrob Agents Chemother 1986, 29: 909-912.

19. Malinverni R, Overholser CD, Bille J, et al. Antibiotic prophylaxis of experimental endocarditis after dental extractions. Circulation 1988, 77: 182-187.

20. Bernard JP, Francioli P, Glauser MP. Vancomycin prophylaxis of experimental Streptococcus sanguis. Inhibition of bacterial adherence rather than bacterial killing. J Clin Invest 1981, 68: 1113-1116.

21. Hall G, Hedstrom SA, Heimdahl A, et al. Prophylactic administration of penicillins for endocarditis does not reduce the incidence of postextraction bacteremia. Clin Infect Dis 1993, 17: 188-194.

22. Hall G, Nord CE, Heimdahl A. Elimination of bacter-aemia after dental extraction: comparison of erythromy-cin and clindamycin for prophylaxis of infective endocarditis. J Antimicrob Chemother 1996, 37: 783-795.

23. Hess J, Holloway Y, Dankert J. Incidence of postextraction bacteremia under penicillin cover in children with cardiac disease. Pediatrics 1983, 71: 554-558.

24. Hall G, Heimdahl A, Nord CE. Effects of prophylactic administration of cefaclor on transient bacteremia after dental extraction. Eur J Clin Microbiol Infect Dis 1996, 15: 646-649.

25. Lowy FD, Chang DS, Neuhaus EG, et al. Effect of penicillin on the adherence of Streptococcus sanguis in vitro and in the rabbit model of endocarditis. J Clin Invest 1983, 71: 668-675.

26. Alkan ML, Beachey EH. Excretion of lipoteichoic acid by group A streptococci. Influence of penicillin on excretion and loss of ability to adhere to human oral mucosal cells. J Clin Invest 1978, 61: 671-677.

27. Moreillon P, Francioli P, Overholser D, et al. Mechanisms of successful amoxicillin prophylaxis of experimental endocarditis due to Streptococcus inter-medius. J Infect Dis 1986, 154: 801-807.

28. Bayer AS, Tu J. Chemoprophylactic efficacy against experimental endocarditis caused by beta-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity. Antimicrob Agents Chemother 1990, 34: 1068-1074.

29. Blatter M, Francioli P. Endocarditis prophylaxis: from experimental models to human recommendation. Eur Heart J 1995, 16: 107-109.

30. Glauser MP, Bernard JP, Moreillon P, et al. Successful single-dose amoxicillin prophylaxis against experimental streptococcal endocarditis: evidence for two mechanisms of protection. J Infect Dis 1983, 147: 568-575.

31. Francioli P, Moreillon P, Glauser MP. Comparison of single doses of amoxicillin or of amoxicillin-gentam-icin for the prevention of endocarditis caused by Streptococcus faecalis and by viridans streptococci. J Infect Dis 1985, 152: 83-89.

32. Malinverni R, Francioli PB, Glauser MP. Comparison of single and multiple doses of prophylactic antibiotics in experimental streptococcal endocarditis. Circulation 1987, 76: 376-382.

33. Entenza JM, Calandra T, Moosmann Y, et al. Teicoplanin versus vancomycin for prophylaxis of experimental Enterococcus faecalis endocarditis in rats. Antimicrob Agents Chemother 1991, 36: 1256-1262.

34. James J, MacFarlane TW, McGowan DA, et al. Failure of post-bacteraemia delayed antibiotic prophylaxis of experimental rabbit endocarditis. J Antimicrob Chemother 1987, 20: 883-885.

35. Rouse MS, Steckelberg JM, Brandt CM, et al. Efficacy of azithromycin or clarithromycin for prophylaxis of viri-dans group streptococcus experimental endocarditis. Antimicrob Agents Chemother 1997, 41: 1673-1676.

36. Vermot D, Entenza JM, Vouillamoz J, et al. Efficacy of clarithromycin versus that of clindamycin for single-dose prophylaxis of experimental streptococcal endocarditis. Antimicrob Agents Chemother 1996, 40: 809-811.

37. Glauser MP, Francioli P. Successful prophylaxis against experimental streptococcal endocarditis with bacterio-static antibiotics. J Infect Dis 1982, 146: 806-810.

38. Roberts GJ. Dentists are innocent! "Everyday" bac-teremia is the real culprit: a review and assessment of the evidence that dental surgical procedures are a principal cause of bacterial endocarditis in children. Pediatr Cardiol 1999, 20: 317-325.

39. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. Clin Infect Dis 1997, 25: 1448-1458.

40. Ramsdale DR, Turner-Stokes L, Advisory Group of the British Cardiac Society Clinical Practice Committee; RCP Clinical Effectiveness and Evaluation Unit. Prophylaxis and treatment of infective endocarditis in adults: a concise guide. Clin Med 2004, 4: 545-550.

41. Danchin N, Duval X, Leport C. Prophylaxis of infective endocarditis: French recommendations 2002. Heart 2005, 91.

42. Steckelberg JM, Wilson WR. Risk factors for infective endocarditis. Infect Dis Clin North Am 1993, 7: 9-19.

43. Levison ME, Abrutyn E. Infective Endocarditis: Current Guidelines on Prophylaxis. Curr Infect Dis Rep 1999, 1: 119-125.

44. ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 1998, 32: 1486-1588.

45. Hayek E, Gring CN, Griffin BP. Mitral valve prolapse. Lancet 2005, 365: 507-518.

46. ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 1998, 32: 1486-1588.

47. CDC National Center for Health Statistics. Health, United States, 2004 with Chartbook on Trends in the

Health of Americans U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, Editor. 2004, Centers for Disease Control and Prevention.

48. Millar BC, Moore JE. Emerging issues in infective endocarditis. Emerg Infect Dis 2004, 10: 1110-1116.

49. Guntheroth WG. How important are dental procedures as a cause of infective endocarditis? Am J Cardiol 1984, 54: 797-801.

50. Strom BL, Abrutyn E, Berlin JA, et al. Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study. Ann Intern Med 1998, 129: 761-769.

51. Pallasch TJ. Antibiotic prophylaxis: problems in paradise. Dent Clin North Am 2003, 47: 665-679.

52. Van der Meer JT, Van Wijk W, Thompson J, et al. Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis. Lancet 1992, 339: 135-139.

53. van der Meer JT, Thompson J, Valkenburg HA, et al. Epidemiology of bacterial endocarditis in The Netherlands. II. Antecedent procedures and use of prophylaxis. Arch Intern Med 1992, 152: 1869-1873.

54. Lacassin F, Hoen B, Leport C, et al. Procedures associated with infective endocarditis in adults. A case control study. Eur Heart J 1995, 16: 1968-1974.

55. Simmons NA, Ball AP, Cawson RA, et al. Antibiotic prophylaxis and infective endocarditis. Lancet 1992, 339: 1292-1293.

56. Horstkotte D, Follath F, Gutschik E, et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J 2004, 25: 267-276.

57. Rajasuo A, Perkki K, Nyfors S, et al. Bacteremia following surgical dental extraction with an emphasis on anaerobic strains. J Dent Res 2004, 83: 170-174.

58. Pallasch TJ, Slots J. Antibiotic prophylaxis and the medically compromised patient. Periodontol 2000, 10: 107-138.

59. Lockhart PB, Durack DT. Oral microflora as a cause of endocarditis and other distant site infections. Infect Dis Clin North Am 1999, 13: 833-850.

60. Heimdahl A, Hall G, Hedberg M, et al. Detection and quantitation by lysis-filtration of bacteremia after different oral surgical procedures. J Clin Microbiol 1990, 28: 2205-2209.

61. Walsh RM, Kumar BN, Tse A, et al. Post-tonsillectomy bac-teraemia in children. J Laryngol Otol 1997, 111: 950-952.

62. Soldado L, Esteban F, Delgado-Rodriguez M, et al. Bacteraemia during tonsillectomy: a study of the factors involved and clinical implications. Clin Otolaryngol Allied Sci 1998, 23: 63-66.

63. Keles E, Kizirgil A, Kaygusuz I, et al. Bacteriemia during mastoidectomy and/or tympanoplasty. Otolaryngol Head Neck Surg 2005, 133: 347-351.

64. Kaygusuz I, Kizirgil A, Karlidag T, et al. Bacteriemia in septoplasty and septorhinoplasty surgery. Rhinology 2003, 41: 76-79.

65. Prophylaxis of infective endocarditis. Revision of the march 1992 consensus conference. Recommendations 2002. M├ędecine et maladies infectieuses 2002, 32: 542-550.

66. Ansley JF, Shapiro NL, Cunningham MJ. Rigid tracheo-bronchoscopy-induced bacteremia in the pediatric population. Arch Otolaryngol Head Neck Surg 1999, 125: 774-776.

67. Yigla M, Oren I, Bentur L, et al. Incidence of bacter-aemia following fibreoptic bronchoscopy. Eur Respir J 1999, 14: 789-791.

68. Botoman VA, Surawicz CM. Bacteremia with gastrointestinal endoscopic procedures. Gastrointest Endosc 1986, 32: 342-346.

69. Nelson DB. Infectious disease complications of GI endoscopy: Part I, endogenous infections. Gastrointest Endosc 2003, 57: 546-556.

70. Zuccaro GJ, Richter JE, Rice TW, et al. Viridans strep-tococcal bacteremia after esophageal stricture dilation. Gastrointest Endosc 1998, 48: 568-573.

71. Nelson DB, Sanderson SJ, Azar MM. Bacteremia with esophageal dilation. Gastrointest Endosc 1998, 48: 563-567.

72. Selby WS, Norton ID, Pokorny CS, et al. Bacteremia and bacterascites after endoscopic sclerotherapy for bleeding esophageal varices and prevention by intravenous cefotaxime: a randomized trial. Gastrointest Endosc 1994, 40: 680-684.

73. Hirota WK, Petersen K, Baron TH, et al. Guidelines for antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc 2003, 58: 475-482.

74. Lo GH, Lai KH, Shen MT, et al. A comparison of the incidence of transient bacteremia and infectious sequelae after sclerotherapy and rubber band ligation of bleeding esophageal varices. Gastrointest Endosc 1994, 40: 675-679.

75. Lorenz R, Herrmann M, Kassem AM, et al. Microbiological examinations and in-vitro testing of different antibiotics in therapeutic endoscopy of the biliary system. Endoscopy 1998, 30: 708-712.

76. Rerknimitr R, Fogel EL, Kalayci C, et al. Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. Gastrointest Endosc 2002, 56: 885-889.

77. Niederau C, Pohlmann U, Lubke H, et al. Prophylactic antibiotic treatment in therapeutic or complicated diagnostic ERCP: results of a randomized controlled clinical study. Gastrointest Endosc 1994, 40: 533-537.

78. Sauter G, Grabein B, Huber G, et al. Antibiotic prophylaxis of infectious complications with endoscopic retrograde cholangiopancreatography. A randomized controlled study. Endoscopy 1990, 22: 164-167.

79. Harris A, Chan AC, Torres-Viera C, et al. Meta-analysis of antibiotic prophylaxis in endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy 1999, 31: 718-724.

80. Adler DG, Jacobson BC, Davila RE, et al. ASGE guideline: complications of EUS. Gastrointest Endosc 2005, 61: 8-12.

81. Janssen J, Konig K, Knop-Hammad V, et al. Frequency of bacteremia after linear EUS of the upper GI tract with and without FNA. Gastrointest Endosc 2004, 59: 339-344.

82. Levy MJ, Norton ID, Wiersema MJS, D.A., et al. Prospective risk assessment of bacteremia and other infectious complications in patients undergoing EUS-guided FNA. Gastrointest Endosc 2003, 57: 672-678.

83. Barawi M, Gottlieb K, Cunha B, et al. A prospective evaluation of the incidence of bacteremia associated with EUS-guided fine-needle aspiration. Gastrointest Endosc 2001, 53: 189-192.

84. London MT, Chapman BA, Faoagali JL, et al. Colonoscopy and bacteraemia: an experience in 50 patients. N Z Med J 1986, 99: 269-271.

85. Low DE, Shoenut JP, Kennedy JK, et al. Prospective assessment of risk of bacteremia with colonoscopy and polypectomy. Dig Dis Sci 1987, 32: 1239-1244.

86. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999, 27: 887-892.

87. Marier R, Valenti AJ, Mardi JA. Gram-negative endocarditis following cystoscopy. J Urol 1978, 119: 134-137.

88. Siroky MB, Moylan R, Austen GJ, et al. Metastatic infection secondary to genitourinary tract sepsis. Am J Med 1976, 61: 351-360.

89. Wittels E, Wright KEJ. Cardiovascular complications of urologic surgery. Urol Clin North Am 1976, 3: 225-237.

90. Bishara J, Leibovici L, Huminer D, et al. Five-year prospective study of bacteraemic urinary tract infection in a single institution. Eur J Clin Microbiol Infect Dis 1997, 16: 563-567.

91. Larsen EH, Gasser TC, Madsen PO. Antimicrobial prophylaxis in urologic surgery. Urol Clin North Am 1986, 13: 591-604.

92. Sullivan NM, Sutter VL, Carter WT, et al. Bacteremia after genitourinary tract manipulation: bacteriological aspects and evaluation of various blood culture systems. Appl Microbiol 1972, 23: 1101-1106.

93. Olson ES, Cookson BD. Do antimicrobials have a role in preventing septicaemia following instrumentation of the urinary tract? J Hosp Infect 2000, 45: 85-97.

94. Murphy DM, Stassen L, Carr ME, et al. Bacteraemia during prostatectomy and other transurethral operations: influence of timing of antibiotic administration. J Clin Pathol 1984, 37: 673-676.

95. Surgeons. AUAAAoO. Antibiotic prophylaxis for uro-logical patients with total joint replacements. J Urol 2003, 169: 1796-1797.

96. Cafferkey MT, Falkiner FR, Gillespie WA, et al. Antibiotics for the prevention of septicaemia in urology. J Antimicrob Chemother 1982, 9: 471-477.

97. Thompson PM, Talbot RW, Packham DA, et al. Transrectal biopsy of the prostate and bacteraemia. Br J Surg 1980, 67: 127-128.

98. Allan WR, Kumar A. Prophylactic mezlocillin for transurethral prostatectomy. Br J Urol 1985, 57: 46-49.

99. Prokocimer P, Quazza M, Gibert C, et al. Short-term prophylactic antibiotics in patients undergoing prostatectomy: report of a double-blind randomized trial with 2 intravenous doses of cefotaxime. J Urol 1986, 135: 60-64.

100. McEntee GP, McPhail S, Mulvin D, et al. Single dose antibiotic prophylaxis in high risk patients undergoing transurethral prostatectomy. Br J Surg 1987, 74: 192-194.

101. Qiang W, Jianchen W, MacDonald R, et al. Antibiotic prophylaxis for transurethral prostatic resection in men with preoperative urine containing less than 100,000 bacteria per ml: a systematic review. J Urol 2005, 173: 1175-1181.

102. Doern GV, Ferraro MJ, Brueggemann AB, et al. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 1996, 40: 891-894.

103. Fluckiger U, Moreillon P, Blaser J, et al. Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats. Antimicrob Agents Chemother 1994, 38: 2846-2849.

104. Tuohy M, Washington JA. Antimicrobial susceptibility of viridans group streptococci. Diagn Microbiol Infect Dis 1997, 29: 277-280.

105. Ioannidou S, Tassios PT, Kotsovili-Tseleni A, et al. Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children. Int J Antimicrob Agents 2001, 17: 195-201.

106. Pfaller MA, Jones RN, Marshall SA, et al. Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group. Diagn Microbiol Infect Dis 1997, 29: 259-263.

107. Teng LJ, Hsueh PR, Chen YC, et al. Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis. J Antimicrob Chemother 1998, 41: 621-627.

108. Smith A, Jackson MS, Kennedy H. Antimicrobial susceptibility of viridans group streptococcal blood isolates to eight antimicrobial agents. Scand J Infect Dis 2004, 36: 259-263.

109. Prabhu RM, Piper KE, Baddour LM, et al. Antimicrobial susceptibility patterns among viridans group streptococcal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to 2002. Antimicrob Agents Chemother 2004, 48: 4463-4465.

110. Fluckiger U, Francioli P, Blaser J, et al. Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci. J Infect Dis 1994, 169: 1397-1400.

111. Dajani AS, Bawdon RE, Berry MC. Oral amoxicillin as prophylaxis for endocarditis: what is the optimal dose? Clin Infect Dis 1994, 18: 157-160.

112. Pfaller MA, Jones RN, Doern GV, et al. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diagn Microbiol Infect Dis 1999, 33: 283-297.

113. Bor DH, Himmelstein DU. Endocarditis prophylaxis for patients with mitral valve prolapse. A quantitative analysis. Am J Med 1984, 76: 711-717.

114. Tzukert AA, Leviner E, Benoliel R, et al. Analysis of the American Heart Association's recommendations for the prevention of infective endocarditis. Oral Surg Oral Med Oral Pathol 1986, 62: 276-279.

115. Hirschhorn LR, Trnka Y, Onderdonk A, et al. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994, 169: 127-133.

116. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998, 40: 1-15.

117. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005, [Epub ahead of print].

118. Wilcox MH, Cunniffe JG, Trundle C, et al. Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect 1996, 34: 23-30.

119. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171: 466-472.

120. Bombassaro AM, Wetmore SJ, John MA. Clostridium difficile colitis following antibiotic prophylaxis for dental procedures. J Can Dent Assoc 2001, 67: 20-22.

121. Ambrose NS, Johnson M, Burdon DW, et al. The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile. J Antimicrob Chemother 1985, 15: 319-326.

122. Privitera G, Scarpellini P, Ortisi G, et al. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother 1991, 35: 208-210.

123. Woodman AJ, Vidic J, Newman HN, et al. Effect of repeated high dose prophylaxis with amoxycillin on the resident oral flora of adult volunteers. J Med Microbiol 1985, 19: 15-23.

124. Hall GE, Baddour LM. Apparent failure of endocarditis prophylaxis caused by penicillin-resistant Streptococcus mitis. Am J Med Sci 2002, 324: 51-53.

125. Marron A, Carratala J, Alcaide F, et al. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients. J Antimicrob Chemother 2001, 47: 87-91.

126. Carratala J, Alcaide F, Fernandez-Sevilla A, et al. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis 1995, 20: 1169-1173.

127. Rice LB. Emergence of vancomycin-resistant entero-cocci. Emerg Infect Dis 2001, 7: 183-187.

128. Rezende NA, Blumberg HM, Metzger BS, et al. Risk factors for methicillin-resistance among patients with Staphylococcus aureus bacteremia at the time of hospital admission. Am J Med Sci 2002, 323: 117-123.

129. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999, 340: 493-501.

130. Fowler VGJ, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005, 293: 3012-3021.

131. Ireland JH, McCarthy JT. Infective Endocarditis in Patients with Kidney Failure: Chronic Dialysis and Kidney Transplant. Curr Infect Dis Rep 2003, 5: 293-299.

132. Martin-Davila P, Fortun J, Navas E, et al. Nosocomial endocarditis in a tertiary hospital: an increasing trend in native valve cases. Chest 2005, 128: 772-779.

133. Chu VH, Cabell CH, Abrutyn E, et al. Native valve endocarditis due to coagulase-negative staphylococci: report of 99 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2004, 39: 1527-1530.

134. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 2003, 111: 1265-1273.

135. Fabbri A, Tacchella A, Belli ML, et al. In vitro activity of sulbactam/ampicillin and ampicillin against methi-cillin-sensitive and methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Chemioterapia 1988, 7: 306-308.

136. Reynolds R, Potz N, Colman M, et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 2004, 53: 1018-1032.

137. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999, 20: 250-278.

138. Haddad SH, Arabi YM, Memish ZA, et al. Nosocomial infective endocarditis in critically ill patients: a report of three cases and review of the literature. Int J Infect Dis 2004, 8: 210-216.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment